Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies

This study provides an overview of camrelizumab use in unselected AEC patients. The real-world effectiveness and safety of camrelizumab are generally consistent with those observed in pivotal trials.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Immunotherapy
Published
2025-03-08
DOI
https://doi.org/10.1007/s00262-025-03970-z
Citations
4
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
8.03

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies

Fengzhuo Cheng, Rongrong Zheng, Jun Zhao, Zishu Wang et al.
4 citations
Cancer Immunology Immunotherapy
Esophageal Cancer Research and Treatment
8.03
article

Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies

Fengzhuo Cheng, Rongrong Zheng, Jun Zhao, Zishu Wang, Zhen Yang, Shuanghu Yuan, Wenjie Deng, Wang Chen, Na Li, Yusheng Wang, Junsheng Wang, Lin Shen, Jiancheng Li, Suyi Li, Zhe Yang, Yinghua Ji, Yanqiao Zhang, Zhihao Lu, Guoping Sun, Dong Qian, Fengming Ran, Lixin Wan, S. H. Zhu
article en
4 citations

Abstract

This study provides an overview of camrelizumab use in unselected AEC patients. The real-world effectiveness and safety of camrelizumab are generally consistent with those observed in pivotal trials.

Cancer Immunology ImmunotherapyVol. 74(4)
Wannan Medical College (CN), Fujian Medical University (CN), Shandong University (CN), Harbin Medical University (CN), Shanxi Medical University (CN), Anhui Medical University (CN), Changzhi Medical College (CN), Peking University (CN), Peking University Cancer Hospital (CN), Ganzhou People's Hospital (CN), Suizhou Central Hospital (CN), Shandong Tumor Hospital (CN), Third Affiliated Hospital of Harbin Medical University (CN), First Affiliated Hospital of Xinxiang Medical University (CN), Nanyang Institute of Technology (CN), Shandong Provincial Hospital (CN), First Hospital of Shanxi Medical University (CN), Anhui Provincial Hospital (CN), First Affiliated Hospital of Anhui Medical University (CN), Jiangsu Hengrui Medicine (China) (CN), Fujian Provincial Cancer Hospital (CN), Second Affiliated Hospital of Anhui Medical University (CN), First Affiliated Hospital of Bengbu Medical College (CN), Hubei Cancer Hospital (CN), Anyang Tumor Hospital (CN), Shandong First Medical University (CN), First Affiliated Hospital of Wannan Medical College (CN), Huazhong University of Science and Technology (CN), Henan Medical University (CN)
Jiangsu Hengrui Medicine
No poverty
Openalex Percentile: Top 3%
Esophageal Cancer Research and Treatment
8.03
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.